RxDoctor Payments Data

Danni Eldred, NP

Nurse Practitioner · Denver, CONPI 1780214551

Payments from drug & device makers

$3,751in general payments, 2019–2025

Across 142 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$414
  • Novartis$244
  • AstraZeneca$236
  • Seagen Inc.$207
  • Pfizer$184
  • Sanofi$171
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$3,38090%
  • Education$37110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,751 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

See all nurse practitioner providers in Colorado

Medicare billing

Part B allowed, 2024
$19,256
Medicare patients
189
Services billed
294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate14$274,727
CalquenceAcalabrutinib Maleate16$259,964
VerzenioAbemaciclib15$216,615
RevlimidLenalidomide12$215,937
BrukinsaZanubrutinib14$201,240
ImbruvicaIbrutinib12$193,833
IbrancePalbociclib11$181,080
NubeqaDarolutamide12$170,239
EliquisApixaban84$98,336
XareltoRivaroxaban35$37,383
Anastrozole206$4,187
Exemestane15$1,934
Tamoxifen Citrate65$1,680
Letrozole53$1,496
Hydroxyurea27$1,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$236$534,69130 claims
PfizerIbrance, Eliquis$184$279,41695 claims
Lilly USA, LLCVerzenio$142$216,61515 claims
Bristol Myers SquibbRevlimid$150$215,93712 claims
Beigene USA, Inc.Brukinsa$68$201,24014 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$170$193,83312 claims
Johnson & JohnsonXarelto$414$37,38335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

Other nurse practitioner in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →